FYARRO (sirolimus protein-bound particles for injectable suspension) (albumin-bound), FDA Approved for Treatment of Locally Advanced Unresectable or Metastatic Malignant Perivascular Epithelioid Cell Tumor, Available at Biologics by McKesson
CARY, N.C., Dec. 22, 2022—Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, was selected […]
REZLIDHIA (olutasidenib), FDA-Approved for Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia, Available at Biologics by McKesson
CARY, N.C., Dec. 19, 2022—Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, has been […]
KRAZATI® (adagrasib), FDA Approved for Treatment of Advanced Non-Small Cell Lung Cancer Harboring the KRASG12C Mutation, Available at Biologics by McKesson
CARY, N.C., Dec. 14, 2022 — Biologics by McKesson, an independent specialty pharmacy focused on oncology and rare disease areas, […]
ELAHERE™ (mirvetuximab soravtansine-gynx), FDA Approved for Platinum-Resistant Ovarian Cancer, Available at Biologics by McKesson
CARY, N.C., December 12, 2022—Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, has been […]